Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Current Deferred Revenue (2020 - 2021)

Atea Pharmaceuticals (AVIR) has 2 years of Current Deferred Revenue data on record, last reported at $192.2 million in Q3 2021.

  • For Q3 2021, Current Deferred Revenue changed N/A year-over-year to $192.2 million; the TTM value through Sep 2021 reached $192.2 million, changed N/A, while the annual FY2020 figure was $301.4 million, N/A changed from the prior year.
  • Current Deferred Revenue reached $192.2 million in Q3 2021 per AVIR's latest filing, down from $225.0 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $301.4 million in Q4 2020 and bottomed at $192.2 million in Q3 2021.